Eric Lefkofsky: Changing the Face of Cancer

Eric Lefkofsky is a renowned entrepreneur and co-founder of Tempus, a technology company that recently developed an operating system to combat cancer. Tempus has been operational since 2015. Cancer affects a significant number of individuals in the world, a situation that pushed Eric Lefkofsky to come up with an analytics machine to help battle the disease. Using the interactive and analytics learning program, doctors can provide personalized care to their patients.

This analytics platform has made significant steps towards fighting cancer. Tempus uses DNA/RNA genomic sequencing services and analyzed molecular and therapeutic data to help doctors make viable decisions by relying on real-time data.

Tempus has also formed alliances with major cancer centers in United States and various learning institutions in order to have access to big data. Access to the data could help the firm develop solutions that would improve the lives of people diagnosed with cancer. Tempus accumulates and reviews radiology scans, clinical records, and pathology images to unveil therapeutic and phenotypic outcomes for each patient. The firm focuses on ensuring that current patients benefit from the data collected during the treatment or management of past cases.

Eric Lefkofsky was raised in Southfield, Michigan. He also graduated from University of Michigan Law School in 1993. He ventured into entrepreneurship after graduation and has been an entrepreneur ever since. He later ventured into data analytics with the aim of improving people’s quality of life. He is the co-founder and chairperson of Groupon. He also co-founded Lightbank, Mediaocean, Uptake Technologies, InnerWorkings, and Echo Global Logistics.

Besides being a senior executive in these organizations, Lefkofsky is also a philanthropist. Together with his wife, they established Lefkofsky Family Foundation, a charitable trust. The foundation’s focus is to accomplish notable initiatives in education, medicine, culture, art, and elemental human rights. That notwithstanding, the organization aims to better the lives of people in the communities it serves. Lefkofsky also serves as a trustee of the Lurie Children’s Hospital in Chicago, the Art Institute of Chicago, The Museum of Science, and Industry and World Business Chicago.

Eric Lefkofsky’s Facebook Page: www.facebook.com/eplefkofsky/

The Oncotarget’s Approaches on Breast Cancer and Its Awardees

You might be looking for articles on treatments for breast cancer. If that’s the case, then you should be able to find value in this article, where it talks about various ways that Oncotarget and Eureka Alert are pushing the studies on the breast cancer cure.

Sure, there are other articles out there that can tell you the same things, but it might only be with Oncotarget that you can find out why you should follow the research today. Shall we move on? Check Oncotarget at scimagojr.com

The Eureka Alert Article About Oncotarget

I think it’s fantastic that we have right now new ways to understand breast cancer cure. I guess it was Nassim Taleb who proposed of the idea of Via Negative, where you get better, and you can get the cure for the illnesses we have in modern days if we get rid of the toxins.

That said, in the Eureka Alert article about Oncotarget, it was shown that there are now new research methods that can push the study of breast cancer to greater heights. One of these researches is the hormone therapy estrogen receptor beta, which has the ability to regulate how your body will react to cancer-causing cells. Follow Oncotarget journal on Twitter.

The PRNewswire Article

On another note, you may also want to consider the fact that Oncotarget has recently awarded four researchers in biomedical cancer science in their efforts to find the therapy needed for breast cancer. These four researchers come from various universities in the world, which include the Aligarh Muslim University, the University of Torino and the National Institute of Immunology India.

One target’s Editor In Chief Mikhail Blagosklonny said that these new awardees will push the discoveries and potentials in cancer research and will make sure that we are on the right path towards finding the cure.

It may also be necessary for your research to know that these four researchers have a contribution to how the new hormone therapy for breast cancer is initiated. These researches already know what the estrogen receptor subtypes can do in the nuclear receptor superfamily to make sure that the answer to people’s cancer problems will then be finally answered.

Listen: https://itunes.apple.com/us/podcast/oncotarget/id1294363732?mt=2

The Inspiration and Truth behind Seattle Genetics; Dr. Clay Siegall

Dr. Siegall is one of the most reliable medical practitioners with a vast knowledge and experience in the field. Well, this did not come as easy as it is said. As he revealed during an interview the idea of establishing a private venture, Seattle Genetics came from his desire for altitude in his career. He also had a desire for medicine, probably coming up with something new and effective in the field, power of technology and unexplored world of some medicine.

Motivated by the desire to see a reversal of those entitled to death due to medical condition have life in abundance all over again. An experience with a family member diagnosed with cancer made him realize that some treatment options are not as effective as they are thought to be. Chemotherapy, for instance, is more draining as compared to amputation and radical surgery which are minimally invasive. This is how Seattle Genetics was formed.

Along with other senior researchers, he did dive into fact-finding about the abnormal growth of cells and how this growth would be contained and treated without having to expose the patient to more adverse effects of heat treatment. Their main mode of treatment is targeted therapy or systemic chemotherapies. Seattle has developed an antibody-drug known as ADCetris which is the first ever FDA approved the drug. This is their best seller and probably won’t be beaten by competitors’ equals. Another awaiting introduction is in partnership with Genentech, Pfizer, and Bayer.

About Dr. Clay Siegall

Dr. Clay Siegall is the Chief Executive Officer of the Seattle based technology company, Seattle Genetics. This firm uses targeted therapy drugs which are more effective than conventional treatment methods. Sharing in his big dream for Seattle Genetics and hunger for a lasting solution, research has extensively been done, trial and experiments conducted.

He revealed he made quite a fortune from Seattle Genetics from selling their drugs and also from drug production partnerships with other legalized companies. The blossom came after their Initial public offer. Dr. Clay Siegall is a Bachelor of Science degree holder in zoology from the University of Maryland and obtained a merited Ph.D. from his alma mater, George Washington University in Genetics.

Eric Lefkofsky Fills the Gap in the Data-Centric Approach to Cancer

So as to treat cancer successfully, doctors require data. But they do not need data about just a few things. In today’s medical research system, the inability to gather data about several things is missing, and this is making it difficult to treat this disease, Erich Lefkofsky, the co-founder and CEO of Tempus, said on Wednesday at the Fortune Brainstorm Health conference in San Diego.

While there is sufficient patient data out there, lack of sources that combine therapeutic data with genomic information is a major problem in the health care industry. Mr. Leftkofsky noted that other than molecular data, doctors need clinical data to be able to fight cancer efficiently. He explained that clinicians need to know which treatments their patients are on and how they are responding instead of only gathering data about their DNA and RNA makeup.

If a clinical researcher is observing several cancer patients taking Herceptin, he needs to get to know why it is working on 40 percent and not 60 percent of these participants. Moreover, the researchers should know what other things are going on with the patients who are not responding positively to the treatment. For example, are they diabetic? Or, are they taking other drugs?

About Eric Lefkofsky

Eric Lefkofsky, a philanthropist who has founded several organizations including Groupon (GRPN), Uptake Technologies, and Lightbank, was inspired to create a platform where doctors can collect adequate data for analysis when his wife was diagnosed with breast cancer. He began to reflect on how truck drivers often get valuable data on how to do their job as he sat in clinics with his wife. This realization motivated him to start an organization with a mission to establish databases and advance the treatment of cancer and named it Tempus.

Other than health, art and culture is another area of the Lefkofskys’ philanthropy. The family’s largest contribution to a single organization to date is seven million U.S. dollars, which they donated to the Steppenwolf Theatre Company. The Lefkofskys’ other major contributions to arts and culture include the $2.5 million to Chicago’s Museum of Contemporary Art and the $ 1.5 million to the Art Institute of Chicago.

Twitter: Twitter.com/lefkofsky

The Dedicated Breast Cancer Fighter, Erick Lefkofsky

The fight against cancer in the present day has intensified. Despite the fact that no cure has been discovered yet, scientists and researchers do not relent. They are still waging war against it in all possible ways. Mr Eric Lefkofsky has joined in the fight and is providing data that will assist in the better treatment of breast cancer.

Eric Lefkofsky is the founder of Tempus. It is a startup cancer-fighting enterprise from Groupon. It aims at providing doctors at the University of Chicago crucial data that will aid in the better administration of treatment to breast cancer patients. The organization has joined forces with the University of Chicago to provide molecular sequencing and analysis for their breast cancer specialists. It has, therefore, created personalized treatment plans for patients from this analysis. It has purposed to analyze data from as many breast cancer patients to help practitioners expose patterns that forecast how patients will respond to treatment. Click here to know more.

Breast cancer is the most common form of cancer. Unfortunately, petite data on the patients is available. It has made the formulation of therapy a hectic task for physicians due to lack of reference points. Therefore, provision of this data is the aim of Tempus as it will help lead to better treatment and to ultimately improved patient outcomes. Hence, it utilizes the services of machines learning and genomic sequencing to assist doctors in making immediate personalized treatment decisions.

Erick Lefkofsky has heavily invested in the healthcare sector. He is a founding partner of Lightbank as well as co-founder and Chairman of Groupon. Moreover, he has served in other organizations like Mediaocean, Echo Global Logistics, and InnerWorking. Also, he has established the Lefkofsky Family Foundation, a private charitable organization. He is a graduate of Michigan University. Eric’s aim is to live in a breast cancer-free society.

Cancer Treatment Centers of America Teams Up For New Cancer Course of Action

Cancer Treatment Centers of America (CTCA) has partnered with NantHealth and Allscripts to put a more personalized system into action that will design custom treatments specific to cancer patients.

The program, called Clinical Pathways, joins together the latest existing cancer research and passes on all pertinent treatment choices. The three started planning the custom result, called eviti, early last year.

According to Wikipedia, CTCA’s Southeastern Regional Medical Center’s Dr. George Daneker said in a statement the collaboration does away with potential speculation by clinicians and provides healing options to patients.

For example, Clinical Pathways will compare treatment alternatives, make access available to up-to-date guidelines as well as provide real-time usefulness. The program will inform all involved of the process without disrupting the flow of information.

By utilizing the program physicians are able to recover facts and statistics from an impartial medical library which takes in more than 2,700 cancer treatment routines. A team of oncologists, oncology nurses as well as an advisory board keeps the library current.

Bobby Reddy, NantHealth senior executive director of medical affairs, said the combined technology which resulted from Cancer Treatment Centers of America’s Clinical Pathways, Allscripts Sunrise EHR and NantHealth’s eviti is proving to be a pivotal moment for the treatment of cancer.

Richard Stephenson, founder and chairman of CTCA, started the centers following the death of his mother from cancer. He became aware of the lack of compassionate and resourceful treatment and made the decision to transform cancer care in her memory.

CTCA’s unique approach combines testing, radiation, chemotherapy and more with supporting therapies that lend a hand to patients before and after treatment.

With its headquarters in Boca Raton, Florida CTCA is a national network of five hospitals that work with adult cancer patients. Facilities are available in Atlanta, Chicago, Philadelphia, Phoenix and Tulsa. Worldwide CTCA offers patients in Mexico City, the Middle East, Latin America and the Caribbean cancer treatment assistance at any of the US centers.

For more information on CTCA follow them on Facebook.

Clay Siegall’s Tireless Quest To Meet Cancer Patients Unmet Needs

As head of Seattle Genetics since 2002, Clay Siegall is proud that the company was the first to receive FDA approval for an antibody-drug conjugate (ADC), which is marketed under the brand name ADCETRIS. Used to treat Hodgkin Lymphoma patients who have not responded to chemotherapy, ADCETRIS’s antibody targets lymphoma cells and then delivers an anticancer drug. Siegall has said that Seattle Genetics is working to gain FDA approval to widen ADCETRIS’s use, which combined with the company’s plans to augment its drug pipeline, interests investors. Under Siegall’s leadership, Seattle Genetics’ stock price has nearly tripled in the last five years.

A frequent featured speaker at industry events, Siegall impresses audiences with his dedication to improving therapies for cancer patients. One of his responsibilities as CEO is to raise capital for Seattle Genetics to continue their research, an area that Siegall excels in. Bringing in more than $350 million from licensing agreements alone, Siegall ensures that Seattle Genetics will continue to develop breakthrough therapies that will benefit cancer patients.

With a dozen new drugs in development, Siegall is focusing on increasing the therapies available for cancer patients, which has been his goal since he co-founded Seattle Genetics in 1998. Xconomy reports that Siegall, in addition to running an ambitious biotechnology company, is on the Board of Governors of the Fred Hutchinson Cancer Research Business Alliance and on the Board of Directors of the Washington Biotechnology and Biomedical Association. Also serving on the Boards of Directors for three private biotechnology companies, Siegall is extremely busy; nevertheless, he told Seeking Alpha “We think we can be the next big important biotech company.” This means Seattle Genetics would need to develop drug after drug, however, when it comes to new ways to meet cancer patients unmet needs, Siegall does not rest.